Skip to main content
. 2012 Apr 6;175(9):950–961. doi: 10.1093/aje/kwr401

Table 4.

Characteristics of 2,279 Infants and Children Enrolled in the US-based Surveillance Monitoring for ART Toxicities Study Between 2007 and 2010

Characteristic Static Cohort (n = 1,240)
 Dynamic Cohort (n = 1,039)
 Total (N = 2,279)
No. % Median (IQR) No. % No. % Median (IQR)
Female 597 48 489 50 1,086 49
Age in years at entry 4.1 (2.0–7.0) 0 0.9 (0–4.5)
Racea
    Black 788 69 715 72 1,503 70
    White or other 359 31 275 28 634 30
    Hispanic/Latino ethnicity 432 35 316 30 748 33
Birth characteristicsb
    Preterm birth (gestation <37 weeks) 238 22 193 21 431 21
    Low birth weight (<2500 g) 225 19 183 19 408 19
Maternal health status prior to labor and deliveryc
    Viral load above 1,000 copies/mL 213 21 138 15 351 18
    CD4+ lymphocyte count less than 250 cells/mm3 163 15 165 18 328 16
    % of CD4+ lymphocytes less than 25% 298 29 289 32 587 30
Maternal substance use during pregnancyd
    Any alcohol use 72 7 92 10 164 8
    Any tobacco use 197 19 170 18 367 18
    Illicit drug use (marijuana, cocaine, or opiates) 86 8 87 9 173 9
    Hard drug use (cocaine or opiates) 31 3 26 3 57 3
Maternal antiretroviral use during pregnancye
    Any antiretroviral use 1,118 96 856 97 1,974 96
    HAART use 845 73 747 85 1,592 78
    HAART use in the first trimester 379 33 368 42 747 37
    Protease inhibitor use 735 63 712 81 1,447 71
    Nonnucleoside reverse transcriptase inhibitor use 216 18 94 11 310 15
    Zidovudine plus lamivudine 876 75 615 70 1,491 73

Abbreviations: HAART, highly active antiretroviral therapy; IQR, interquartile range.

a

A total of 142 subjects did not report their race and 4 did not report their ethnicity.

b

Data on gestational age at birth were missing for 238 children and data on birth weight were missing for 143.

c

Data on maternal viral load were missing for 321 subjects, data on maternal CD4+ lymphocyte count were missing for 282 subjects, and data on maternal percentage of CD4+ lymphocytes were missing for 347 subjects. Maternal health status measures were the latest available before labor or delivery.

d

Data on maternal substance use during pregnancy were missing for 291 subjects, primarily because of nonenrollment of mothers in the static cohort.

e

Data on maternal antiretroviral drug use during pregnancy were missing for 228 women; all percentages in the table were calculated among those for whom we had data.